Factors related to the chronicity and evolution of hepatitis C infection in patients co- infected by the human immunodeficiency virus  R. Pérez-Cano, C. Fernández-Gutiérrez, A. López-Suárez, J. Mira, J.A. Girón-González  Clinical Microbiology and Infection  Volume 8, Issue 9, Pages 589-597 (September 2002) DOI: 10.1046/j.1469-0691.2002.00437.x Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Evolution of mean HCV viremia at 3, 6 and 12 months. (a) Hepatitis C genotype 1a (n = 7) (♦), genotype 1b (n = 7) (▴), genotype 3 a (n = 9) (▪) and genotype 4c/4d (n = 4) (♦). (b) Baseline HCV viremia: >6 log copies/mL (n = 8) (⨕), <6 log copies/mL (n = 22) (▴). Clinical Microbiology and Infection 2002 8, 589-597DOI: (10.1046/j.1469-0691.2002.00437.x) Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Evolution of mean HCV viremia at 3, 6 and 12 months. (a) Baseline HIV viremia: <3.7 log copies/mL (n = 6) (⨕), 3.7–5 log copies/mL (n = 16) (▴), >5 log copies/mL (n = 8) (▪). (b) Baseline CD4+ T-cell counts/mm3: >500 (n = 13) (⨕), 200–500 (n = 13) (▴), <200 (n = 4) (▪). (c) Immune response (increase >25% of baseline CD4+ T-cell count) after 12 months of therapy: responders (n = 8) (⨕), non-responders (n = 22) (▴). (d) Virological response (decrease >1 log copies/mL of baseline HIV load) after 12 months of therapy: responders (n = 12) (⨕), non-responders (n = 18) (▪). Clinical Microbiology and Infection 2002 8, 589-597DOI: (10.1046/j.1469-0691.2002.00437.x) Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions